Introduction
Treatment strategies for children and adolescents with acute lymphoblastic leukemia (ALL) developed over the past few decades have managed to cure up to 90% of cases. 1, 2 While these advancements are encouraging, the most common cause of treatment failure stems from patients who are either refractory to chemotherapy or experience one or more relapse of disease, which occurs in up to 20% of children 3 with overall poor outcomes. Success rates of anywhere from 30% to 50% (as defined by 5-year disease-free survival) can be achieved using current intensive chemotherapy treatments in concordance with allogeneic hematopoietic stem cell transplantation (HSCT). 4 The variance in outcome is dependent on a multitude of factors, with the two most important being length of first complete remission (CR) and site of relapse. 5 However, children who experience two or more relapses of disease have an even more dismal prognosis, with 5-year disease-free survival rates of 27% and 15% in children who achieve a second and third CR, respectively. 6 Prior to the approval of tisagenlecleucel, the US Food and Drug Administration (FDA) approved two drugs specifically for children with relapsed or refractory ALL. Clofarabine, a nucleoside analog, showed a 30% response rate for a median CR duration of 6 weeks, in a Phase II study involving 61 pediatric patients. 7 It was FDA approved in 2004. Blinatumomab, a CD3/CD19 bispecific antibody, demonstrated in a Phase I/II study consisting of 70 children that a CR was achieved in 39% of patients. 8 While the success of blinatumomab compared favorably with other treatment strategies for similar relapsed patients 9 leading to its FDA approval in 2017, remission rates were still below 50%. In addition, durability was difficult to determine given that patients were allowed to withdraw from threatment, after two cycles, for consolidation chemotherapy or allogeneic HSCT. Fortunately, chimeric antigen receptor (CAR) T-cell therapy can provide high remission rates with durable survival submit your manuscript | www.dovepress.com
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Forsberg et al benefits, leading to its FDA approval in 2017 for the treatment of relapsed/refractory pediatric and young adult ALL.
CAR T-cell overview
CAR T-cells are a powerful tool that allows for the specific targeting of tumor cells with engineered T cells. 10 These T cells express synthetic receptors on their cell membrane designed to recognize specific antigens overexpressed on tumor cells in a major histocompatibility complex independent manner. 11 This is achieved through the synthesis of a single-chain variable fragment (scFv) consisting of the variable regions of heavy and light chains from a monoclonal antibody specific for a given tumor antigen. 12 The scFv is cloned into a genetic construct that includes a hinge domain, a transmembrane segment, and the CD3ζ chain in the construction of first-generation CARs. 13 More recent CARs incorporate one (second-generation) or two (third-generation) intracellular signaling domains from costimulatory molecules such as CD28 or 4-1BB. [14] [15] [16] [17] [18] After inserting the CAR construct into a viral vector, 19 autologous or allogeneic T cells are transduced with the viral vector to express the CAR on their cell surface. 20 These CAR-expressing T cells are then expanded and infused directly into the patient, where they specifically target tumor cells expressing the antigen recognized by the scFv. CAR T-cell therapy is not without side effects, one of which being cytokine release syndrome (CRS). CRS is characterized by increased levels of inflammatory cytokines such as IL-6 and interferon γ (IFNγ) in the patient, which can be fatal if untreated. 21, 22 Other side effects include tumor lysis syndrome, 23 neurotoxicity, 24 and on-target, off-tumor effects, 25 a condition where CAR T-cells recognize their antigen on normal cells, resulting in destruction of healthy tissue. In the context of treatment for B-ALL, the destruction of healthy tissue results in low numbers or absence of B cells (B-cell aplasia), leading to hypogammaglobulinemia.
Development of CTL019
Initial second-generation CARs were constructed with the addition of the CD28 signaling domain into existing firstgeneration CAR constructs. The introduction of the CD28 domain enhanced IFNγ and IL-2 secretion as well as the proliferative capacity of CAR T-cells in vitro. 14, 15 The in vivo antitumor capabilities of these CARs were also enhanced in xenogeneic and syngeneic colon carcinoma mouse models. 26 A subsequent study demonstrated that costimulatory domains of the tumor necrosis factor receptor family, which includes CD137 (4-1BB), could also be utilized in combination with CD3ζ demonstrating similar effects to those seen in CD28 CARs.
27 CD137 signaling sustains cytotoxic T-cell activity, 28 favors CD8-positive T-cell expansion, 29 and has been shown to be vital in the antitumor response in animal models and in humans. 30, 31 From here, both CD28 and CD137 signaling domains were utilized in the development of CARs against B-ALL. 30, [32] [33] [34] CD19 was chosen as a target for B-ALL due to its high expression on most malignant B cells, while at the same time lacking expression on hematopoietic stem cells, limiting the risk of aplastic anemia. [35] [36] [37] [38] Secondary B-cell aplasia could be managed with immunoglobulin infusions similar to children with agammaglobulinemia. The first direct comparison of CD19-specific second-generation CARs containing a CD137 or CD28 signaling domain was performed in preclinical models. 34 In this study, NOD-SCID-γ c -/-(NSG) mice were engrafted with a human pre-B-cell ALL and then treated with CD137 or CD28 expressing CD19 CAR T-cells. 34 The results demonstrated not only that a significantly higher percentage of NSG mice treated with CD19-CD137 CAR T-cells remained leukemia free but also that CD19-CD137 CAR T-cells could be detected in the spleen 6 months after transfer. 34 The superior antileukemic activity and prolonged persistence of CD19-CD137 CAR T-cells, specifically CTL019 (Figure 1 ), opened the door for their use in initial human trials.
early successes of CTL019
Early applications of CTL019 in humans provided very encouraging results. Three adult patients ranging in age from 64 to 77 years with chemotherapy-resistant chronic lymphocytic leukemia (CLL) were given CTL019 following extensive pretreatment with various biological and chemotherapy regimens. Two of the three patients achieved a CR to CTL019 therapy with the other patient showing a partial response. 39, 40 Importantly, no detectable CLL was present in the bone marrow or circulating blood 6 months after treatment in the two patients with a CR, with remissions extending for more than 10 months. 39, 40 Additionally, functional CTL019 cells were present for at least 6 months, with each cell on average expanding greater than 1,000-fold and eradicating at least 1,000 CLL cells.
Following the initial success of CTL019 in the treatment of adult CLL, a pilot trial investigating the efficacy of CTL019 in children with refractory and relapsed B-ALL was initiated. 41 Two children aged 7 (patient 1) and 10 (patient 2) years were treated with CTL019 after both patients had experienced a second relapse of B-ALL. 41 Robust expansion was observed in both patients, with CTL019 T cells making up to 72% and 34% of total circulating T cells in patient 1 and 
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CAR T-cells for B-ALL patient 2, respectively. 41 As seen in the adult CLL patients, the infused CAR T-cells persisted for at least 6 months and expanded to a level that was more than 1,000 times the original amount. 41 Most importantly, both patients achieved CR, with one ongoing at the time of publication, 11 months after initial treatment. 41 The other patient experienced a CD19-relapse, indicating that it was not due to nonfunctional CTL019 T cells. 41 The initial success of CTL019 T-cell therapy in the treatment of pediatric relapsed/refractory B-ALL led to clinical trials with larger cohorts, producing even more noteworthy results.
Clinical trials of CTL019
In a single institution pediatric trial, 30 children and adults with relapsed/refractory B-ALL (of which 25 were 5-22 years of age) were given CTL019. 23 A CR was achieved in 90% of patients, with 6-month disease-free survival of 67% and overall survival of 78%. Of note was the 73% probability of a patient who had achieved remission to experience relapsefree B-cell aplasia over the same 6-month time period. A clinical trial (KTE-C19) investigating the efficacy of a second-generation CAR T-cell containing a CD28 signaling domain in the treatment of pediatric B-ALL also demonstrated impressive results, with few differences to CTL019. For instance, only 70% of patients who were treated with the second-generation CD28 CAR T-cells achieved a CR according to the report on the first 21 patients, 42 a percentage that fell to 61% when the total cohort of 38 patients were analyzed. 43 Furthermore, B-cell recovery was observed at 28 days post-treatment in 13 of the 14 responding patients, demonstrating the superior persistence of CD137-expressing CTL019 compared with those with a CD28 signaling domain. A subsequent trial by the same group treated an additional 59 pediatric patients, aged 20 months to 24 years, with CTL019. 44 CR rates reached 93% one-month postinfusion in this larger cohort. Disease-free survival numbers were also improved at 6 months with 76%, and overall survival was 79% at 12 months. B-cell aplasia was observed in 24 of the 34 (70.6%) patients with ongoing CR at the time of last assessment.
Based on the success of the previous two single-center clinical trials, a global study of CTL019 therapy was initiated at 25 sites in 11 countries across North America, Europe, Asia, and Australia. 45 In this multicenter study, 75 pediatric and young adult patients underwent CTL019 infusion. CR rates at 3 months postinfusion remained high (81%), while disease-free survival was 73% at 6 months and 50% at 12 months. The median duration of remission was not reached, which compares favorably with the median remission rate of 17.7 months seen in the KTE-C19 trial. With overall survival numbers of 90% at 6 months and 76% at 12 months, the reproducibility and feasibility of CTL019 therapy were conclusively demonstrated, leading to FDA approval of CTL019 as tisagenlecleucel on August 30, 2017.
Comparing overall remission rates across separate studies can be misleading, as researchers choose to report different statistics. For example, the KTE-C19 study reported CR and overall survival rates based on an intent-to-treat 
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Forsberg et al analysis, while some of the CTL019 studies only reported rates based on patients who received a CAR T-cell infusion. If intent-to-treat analysis is compared between the CTL019 and KTE-C19 studies, initial CR rates are very similar. Future studies might consider reporting rates of event-free survival, relapse-free survival, and overall survival on an intent-to-treat basis, as all these parameters are necessary and informative in determining the efficacy of CAR T-cell therapies in the real world. The percentages for all clinical trials discussed above are reported in Table 1 .
Challenges with CTL019 therapy
There are substantial risks associated with CAR T-cell therapy, primary among them being CRS. In the clinical trials of CTL019 mentioned earlier, anywhere from 77% to 100% of patients experienced an episode of CRS, with 27%-37% presenting with severe CRS requiring treatment with the anti-IL6 receptor agent tocilizumab, and in many cases, corticosteroids. The development of CRS was followed in the first 39 patients treated with CTL019 to characterize the timing and severity of CRS. 46 This retrospective cohort study found that 46% of patients followed developed grade 3 or 4 CRS, with prolonged fever and organ dysfunction. Institutional preparation for the management of CRS, as well as for the rest of CTL019 treatment, from leukapheresis to infusion, is reviewed elsewhere. 47 Neurotoxicity, or CAR T-related encephalopathy syndrome (CRES), can occur before, in association with, or after CRS. Around 40% of patients who received a CTL019 infusion experienced some sort of neurologic event, the most common being encephalopathy, confusion, delirium, tremors, agitation, somnolence, and hallucinations. The exact causes of neurologic events are currently unknown, and almost all cases resolve themselves without intervention beyond standard supportive care. Due to the potential severity of CRS and CRES, the FDA limited administration of tisagenlecleucel to just over 40 certified treatment centers under a risk evaluation and mitigation strategy (REMS) program with elements to assure safe use (ETASU). The REMS/ETASU program ensures that high-grade CRS and CRES will be monitored post-FDA approval.
One limitation of CAR T therapy is insufficient T-cell collection during apheresis. Many children are heavily pretreated from prior chemotherapy and have subsequent lymphopenia that preclude obtaining an adequate leukapheresis product to generate CAR T-cells. In an analysis of apheresis efficiency conducted on three pediatric/young adult CAR T-cell trials, it was found that the target of 2×10 9 CD3+ cells was achieved in 55 of 71 (77%) patients, while 69 of 71 (97%) patients reached the minimum number of 0.6×10 9 CD3+ cells. 48 Of note, 16 patients with yields below the target had significantly lower percentages and overall numbers of CD3+ cells compared with patients who achieved the target. 48 Efforts have been made to construct a universal CAR T-cell, one that could be used as an "offthe-shelf" therapy for patients whose apheresis may not be feasible due to severe lymphopenia. This universal CAR T-cell, termed UCART19, has been genetically engineered to not only express the CD19 targeting CAR construct but also knock out the endogenous TRAC locus and CD52 using transcription activator-like effector nucleases. 49 Removal of the endogenous TRAC locus aids in the prevention of UCART19 exhaustion, while the lack of CD52 expression renders these cells resistant to the anti-CD52 monoclonal antibody alemtuzumab. Endogenous mature T and B cells are depleted with the administration of alemtuzumab, which can be given either before or concurrently with UCART19 infusion, enhancing its engraftment. However, boosting UCART19 engraftment with alemtuzumab is not without risk, as its use has been linked to significant increases in opportunistic infections such as cytomegalovirus reactivation. 50 Finally, UCART19 also includes an RQR8 "safety switch" that allows for targeted elimination of RQR8 + cells by the anti-CD20 antibody rituximab. Initial uses of UCART19 in infants unable to generate enough T cells for autologous CAR T-cell therapy have been promising, with 
1577
CAR T-cells for B-ALL both patients achieving CR at Day 28 postinfusion. 49 There are currently two ongoing clinical trials investigating the efficacy of UCART19 therapy, one in adults (NCT02746952) and the other in pediatric patients (NCT02808442) with relapsed or refractory B-ALL. Universal allogeneic CAR T-cells have the potential to elicit host immune responses, a problem that may be addressed by knocking out human leukocyte antigen (HLA) class I. However, such HLA class I-deficient cells would remain susceptible to deletion through the "missing-self recognition" ability of natural killer (NK) cells. Researchers have addressed this problem in human pluripotent stem cells, where HLA class I genes A, B, and C have been knocked out, with an HLA-E single-chain dimer fused to beta-2 microglobulin being knocked in. 51 These cells are not recognized as allogeneic by host T cells and are resistant to NK-mediated lysis. The application of this strategy to CAR T-cells may facilitate the generation of a safer universal product.
In an attempt to limit the exclusion of research participant enrollment, a clinical trial was initiated by Gardner et al with a defined formulation of CAR T-cell therapy. 52 In this trial, a CD19 CAR product with a 1:1 CD4:CD8 T-cell ratio, uniform CAR expression, and limited effector differentiation was manufactured for 93% of the pediatric and young adult patients enrolled. Furthermore, CR was achieved in 89% of the intent-to-treat population, an important advancement compared with prior trials, where up to 24% of patients were excluded based on a predicted failure to produce a CAR T-cell product. 53 The estimated 12-month disease-free survival was 50.8%, with a 12-month overall survival of 69.5%. CD19-relapse was seen in seven patients, a type of relapse that was also seen in the CTL019 clinical trials.
Additional sources of variation between clinical trials of CD19 CAR T-cell therapies are the drugs/dosages used for lymphodepletion, as well as the number of CAR T-cells infused into the patient ( Table 2 ). The most common /kg in the CTL019 Phase I trial. 23 Relapses after CD19 CAR T-cell therapy can be CD19+ or CD19-. It is unknown if CD19+ relapses can be salvaged with additional infusions of CAR T-cells. In an effort to treat CD19-relapse patients, other B-cell-specific antigens have been investigated for selection as targets for novel CAR T-cell generation ( Figure 2 ). Promising new single antigen CARs have been developed for the treatment of B-cell malignancies that target ROR1, 54 CD20, 55 CD22, 56 and thymic stromal lymphopoietin receptor. 57 Worldwide ongoing clinical trials investigating CAR T-cell therapy for pediatric B-ALL are available (Table 3) . Of note, a bispecific CAR targeting the B-cell antigens CD19 and CD20 simultaneously has shown encouraging results, 58, 59 while a separate bispecific CAR targeting CD19 and CD22 is currently being tested in an ongoing clinical trial (NCT03241940). A successful clinical trial has been conducted that treated relapsed B-ALL patients who had previously undergone CTL019 infusion, but then experienced a CD19-relapse, with CD22 CAR T-cells. 60 Seventy-three percent of patients who received 1×10 6 CD22 CAR T-cells per kilogram body weight achieved a CR, including 5/5 patients with CD19-B-ALL. Remissions were not durable as nine patients relapsed, seven of which were associated with diminished CD22 surface expression. Finally, the efficacy of a sequential infusion of anti-CD19 and anti-CD20 CAR T-cells as a single treatment is also currently being investigated (NCT03207178).
Potential future directions of CD19 CAR T therapy
Ongoing preclinical research in CAR T-cell therapy could potentially be used to enhance the efficacy and safety profile of CD19-directed CARs. One method to reduce on-target off-tumor toxicity is through the development of a tunable CAR T-cell. This can be achieved with an "on" or an "off" switch whose activation is dependent on the administration of a small molecule. In the case of "on" switch CARs, research has demonstrated that the CD19 binding scFv domain can be separated from the intracellular signaling domain, with their fusion being dependent on the small molecule rapalog. 61 A different type of "on" switch has also been developed, where the expression of the CD19 CAR construct is dependent on the 
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Forsberg et al administration of doxycycline. 62 CAR T-cell activity could also be controlled through the activation of an "off" switch. In this scenario, the dimerization of caspase-9, engineered to be part of the cytoplasmic domain, is made inducible through the administration of a specific small molecule. A recent study has shown that .90% of CARs can be induced to undergo apoptosis using this approach, with the percentage of apoptotic cells dependent on the amount of caspase-9 binding small molecules administered. 63 Both "on" and "off" switch CAR T-cells would allow physicians to precisely control the timing and dosage of CAR T-cell activation.
A major factor contributing to CD19 CAR T-cell exhaustion is the constitutively active cytoplasmic signaling domains. Incorporation of the CAR construct by lentiviral or retroviral transduction can result in overexpression and contribute to low-level constitutive (tonic) signaling in an antigen-independent manner. 64 With the recent advancement in genome editing technology, it is now possible to directly target the genomic integration of the CAR transgene. A recent study used CRISPR/Cas9 to direct genomic integration of a CAR construct to the T-cell receptor locus (TRAC). 65 Results demonstrated not only robust CAR expression but also enhanced T-cell potency, a reduction of inhibitory receptor expression characteristic of exhaustion (such as PD-1) and prevention of tonic signaling. CRISPR/Cas9 has also been used to generate PD-1 knockout CD19 CAR T-cells, which was demonstrated to enhance CAR T-cell-mediated killing of tumor cells in vitro and increased clearance of PD-L1+ tumor xenografts in vivo. 66 In a recent study, researchers reported on the unique case of a 78-year-old patient who had undergone CTL019 therapy for relapsed/refractory CLL. 67 At peak response in this patient, it was discovered that 94% of CD19 CAR T-cells originated from a single clone in which CTL019 transgene integration occurred in the TET2 gene, disrupting its function. 67 Further analysis revealed that TET2-disrupted CART T cells had a greater proliferative capacity, increased levels of degranulation, and exhibited a central memory phenotype. This patient remained relapse-free 5 years postinfusion. 67 This surprising discovery, when combined with CRISPR genome editing tools, suggests that disruption of TET2 locus may increase the potency of CTL019 cells. 
CAR T-cells for B-ALL
Besides enhancing CAR T function through innovative bioengineering, one could imagine using tisagenlecleucel either for first relapse or upfront for patients with high risk or very high-risk disease. Because chemotherapy and allogeneic HSCT are associated with long-term, end-organ toxicities, usage of tisagenlecleucel has appeal since most of the toxicity appears in the first 30-60 days after infusion. Other than secondary B-cell aplasia, long-term toxicities have yet to be reported. Using CAR T earlier in treatment, such as when there is little to no blast burden after induction chemotherapy, may reduce the risk of severe CRS because bone marrow blast counts .50% correlate with severe CRS. 23 In addition, it is not yet known if tisagenlecleucel is best used as a bridge to allogeneic HSCT or as a standalone curative therapy.
Access to CAR T-cell therapy
An emerging bioethical concern regarding CAR T-cell therapy is access -primarily overcoming geographical barriers and financial barriers. Providing access to CAR T-cell therapy globally involves a broader improvement in medical facilities and the development of subsidized oncology diagnosis and treatment facilities. Within high-income countries, the primary barriers currently are cost and reimbursement strategies. Manufacturers of CAR T-cell therapies are working with governments to streamline reimbursements and implement new pricing models and have justified the high one-time cost of CAR T-cell therapies, 68, 69 while patient advocates and government representatives question the high sticker price of these therapies. 70 It is hoped that further improvements in technology and wider adoption of CAR T-cell therapy will ultimately reduce its cost and increase its availability to a larger segment of the population.
For geographical barriers, there is limited access to standard infrastructure globally for cancer care including access to radiation (.50% of the world population lack access) 71 and publicly funded pathology services (only 26% of lowincome countries have access).
72 CAR T-cell therapy delivery requires facilities and expertise exceeding those required for bone marrow transplantation. Currently, 57% of cancer cases occur in low-and middle-income countries, and 65% of cancer deaths occur in those countries as well. 71 It is also likely that many cancers that are diagnosed through regular screening and accessibility to pathology services are underreported in those numbers. Given these broad trends, methods for increasing global access to oncology and specifically to CAR T-cell therapy need to be developed.
CAR T-cell therapy costs more than other leading cancer therapies -tisagenlecleucel has been made available at a price of $475,000 in the USA, while comparable new orally administered cancer medicines cost at least $135,000 per year as of 2014. 73 This high cost places it out of reach for most patients paying out-of-pocket and increases the burden on private and public insurers. 74 Novartis has proposed an outcome-based agreement, or a "money-back guarantee," for tisagenlecleucel: the price of the drug is refunded in case of failed treatment within the first month. 73 However, it should be noted that a significant number of patients who are in CR at 1 month will later relapse with disease. In addition, the exact terms of the outcome-based agreement are not publicly available. This uncertainty prompted a letter from members of Congress to Novartis asking for clarification on a number of issues including who the responsible party is for reimbursement, and what the specific criteria is for determining a successful 1-month response, among others. 70 Tisagenlecleucel has been approved for refractory diffuse large B-cell lymphoma recently, 75 which is the primary indication for the other approved CAR T-cell product axicabtagene ciloleucel. Announcements from Novartis have indicated that the price of tisagenlecleucel will be based on indication, meaning that the price of the drug will vary depending on the clinical condition it is being used for. 76 One analysis argued that indication-based pricing can help increase access to oncology medications. 76 Such an approach lowered the price of tisagenlecleucel to $373,000 for use against large B-cell lymphomas, pricing it competitively with axicabtagene ciloleucel. 77 Pricing of CAR T-cell therapy has remained contentious since their approval in August 2017. 78 While the Centers for Medicare and Medicaid Services (CMS) have issued statements stating their commitment toward the "development of innovative pricing systems that reflect value delivered to patients," 79 there have not been any definitive statements outlining these systems. The CMS decides on reimbursement of medical care for patients receiving public subsidies for health care within the USA; collectively, they are responsible for payment of health care expenses for 72 million American citizens. 80 The ambiguity in CMS pricing has been questioned by a select group of members of the US House of Representatives 70 and one of the largest private insurers in the USA. 81 An analysis of the effectiveness and value of CAR T-cell therapies for B-cell cancers by the Institute for Clinical and Economic Review, an independent nonprofit organization, found that, "these therapies seem to be priced in alignment with clinical benefits over a lifetime time horizon." 82 They found that tisagenlecleucel provided at least seven more quality-adjusted life years (QALY) compared with clofarabine. The cost difference between tisagenlecleucel and clofarabine indicated that tisagenlecleucel is cost-effective submit your manuscript | www.dovepress.com
Dovepress
1582
Forsberg et al if a QALY is valued .$45,871. Current estimations indicate that the minimum value of a QALY is around $50,000 and should be higher. 83 Analyses of cost-effectiveness performed by Novartis funded researchers have reached similar conclusions within the US context 68 and within the UK. 69 These political and ethical pressures to increase access to CAR T-cell therapies are likely to shape the standards by how CAR T-cell therapies are deployed for the next decade.
Conclusion
Prior advancements in the treatment of relapsed or refractory pediatric B-ALL have been limited by low 5-year survival, with early bone marrow relapses far too common. 84 CTL019, now known as tisagenlecleucel, is the first gene therapy and CAR T-cell therapy to be FDA approved, and its early success provides a new hope for the thousands of children and young adults who relapse with B-ALL each year. The efficacy of CAR T-cell therapy will likely be improved due to the optimization of its delivery, as well as new advancements in CAR T-cell engineering. As we scratch the surface of personalized medicine through adoptive cell therapy with CAR T-cells, the future of relapsed or refractory pediatric B-ALL treatment looks bright. 
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